A mixed performance in the stock price over the year has left investors with either an optimistic or pessimistic outlook, depending on their point of view. The metric has seen a significant loss of -50.05% since the start of this calendar year. Looking back over the last six months, we can see a stronger performance of -74.22%. Over the past 30 days, the price of FATE has leaped by -13.40%. And in the last five days, it has surged by 3.07%.
The current stock price for Fate Therapeutics Inc. (FATE) is $5.04. The stock experienced a significant increase during the last trading session, reaching $5.34 after opening at $5.34. It dipped to a low of $4.99 before ultimately closing at $5.34.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
Sponsored
Fate Therapeutics Inc.’s stock has seen a rocky market performance. The company’s stock achieved a 1-year high of $37.13 on 08/08/22, and the lowest price during that time was $4.02, recorded on 01/06/23.
52-week price history of FATE Stock
The history of a stock’s 52-week high and low prices can provide important information about its current state and future potential. Fate Therapeutics Inc.’s current trading price is -86.43% away from its 52-week high, while its distance from the 52-week low is 25.37%. The stock’s price range for this period has been between $4.02 and $37.13. The Healthcare sector company’s shares saw a trading volume of about 2.28 million for the day, which was lower than the average daily volume of 2.69 million over the last three months.
The Connection Between Financial Performance and Market Capitalization
Fate Therapeutics Inc. (FATE) has experienced a quarterly decline of -12.95% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 486.91M and boasts a workforce of 551 employees.
Expert Opinions: Analysts’ Ratings for Fate Therapeutics Inc.
As of right now, 6 analysts are rating Fate Therapeutics Inc. as a BUY, 1 of the polled analysts branded the stock as an OVERWEIGHT, 14 analysts are recommending to HOLD this stock, 1 of them gave the stock UNDERWEIGHT rating, and 1 analyst is rating the stock as SELL.
How Moving Averages and Trading Volume Data Work Together
Based on Barchart.com data, the company’s moving average over the 100-day period was 5.90, with a change in price of -5.05. Similarly, Fate Therapeutics Inc. recorded 3,294,503 in trading volume during the last 100 days, posting a change of -50.05%.
FATE’s Debt-to-Equity Ratio: A Comprehensive Review
A key metric for assessing a company’s financial well-being and market status is the debt-to-equity (D/E) ratio. This ratio is derived by dividing a company’s total liabilities by its shareholders’ equity, and it demonstrates the level of debt a company uses to support its assets relative to shareholder equity. At the time of writing, the total D/E ratio for FATE stands at 0.00. Similarly, the long-term debt-to-equity ratio is also 0.00.
FATE Stock Stochastic Average
As of today, the raw stochastic average of Fate Therapeutics Inc. over the past 50 days is 15.03%. This is a decrease compared to the raw stochastic average of the last 20 days, which was recorded at 16.13%. Additionally, the Stochastic %K and %D values for the company were 29.21% and 29.33%, respectively, over the past 20 days.
